Publication

Structurally-engineered fatty acid 1024 (SEFA-1024) improves diet-induced obesity, insulin resistance, and fatty liver disease

Lipids 57(4-5):241-255, 2022

Secor JD, Cho BS, Yu LJ, Pan A, Ko VH, Dao DT, Feigh M, Anez-Bustillos L, Fell GL, Fraser DA, Gura KM, Puder M

View publication

Subjects

Therapeutic Area Mouse DIO rat ob/ob mouse Compound Method/Endpoint Species Body weight Rat Blood biochemistry Non-alcoholic steatohepatitis/Metabolic dysfunction-associated steatohepatitis (NASH/MASH)Obesity Oral glucose tolerance test (OGTT)Linagliptin Real-time food intake/activity analysis SEFA-1024

Share this page

Resource Library

Related resources

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models

Metabolic, biochemical, histopathological, and transcriptomic effects of dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Prophylactic and therapeutic hepatoprotective effects of semaglutide in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis

Animal models of type 2 diabetes, obesity and nonalcoholic steatohepatitis – clinical translatability and applicability in preclinical drug development

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650